metaEvidence - overview

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1) 1
mCRC - 2nd line (L2) 3
endometrial cancer 1
esophageal cancer (EC)

immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenvatinib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs taxanes
vs paclitaxel

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

button bars forest bayes pooled summary circles


			deaths (OS)
endometrial cancer endometrial cancer
versus doxorubicin
	pembrolizumab plus lenvatinib vs. doxorubicin	1

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open